FLUOGUIDE A/S DK -1 (F:96X) — Market Cap & Net Worth
Market Cap & Net Worth: FLUOGUIDE A/S DK -1 (96X)
FLUOGUIDE A/S DK -1 (F:96X) has a market capitalization of $57.06 Million (€48.81 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #21374 globally and #1914 in its home market, demonstrating a 1.10% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying FLUOGUIDE A/S DK -1's stock price €3.69 by its total outstanding shares 16349313 (16.35 Million). Analyse FLUOGUIDE A/S DK -1 (96X) cash flow conversion to see how efficiently the company converts income to cash.
FLUOGUIDE A/S DK -1 Market Cap History: 2021 to 2026
FLUOGUIDE A/S DK -1's market capitalization history from 2021 to 2026. Data shows change from $159.03 Million to $70.53 Million (-22.62% CAGR).
FLUOGUIDE A/S DK -1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how FLUOGUIDE A/S DK -1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 96X by Market Capitalization
Companies near FLUOGUIDE A/S DK -1 in the global market cap rankings as of May 5, 2026.
Key companies related to FLUOGUIDE A/S DK -1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
FLUOGUIDE A/S DK -1 Historical Marketcap From 2021 to 2026
Between 2021 and today, FLUOGUIDE A/S DK -1's market cap moved from $159.03 Million to $ 70.53 Million, with a yearly change of -22.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €70.53 Million | +19.81% |
| 2025 | €58.87 Million | -1.60% |
| 2024 | €59.83 Million | -37.40% |
| 2023 | €95.57 Million | +52.91% |
| 2022 | €62.50 Million | -60.70% |
| 2021 | €159.03 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of FLUOGUIDE A/S DK -1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $57.06 Million USD |
| MoneyControl | $57.06 Million USD |
| MarketWatch | $57.06 Million USD |
| marketcap.company | $57.06 Million USD |
| Reuters | $57.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About FLUOGUIDE A/S DK -1
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatmen… Read more